SG10202111399YA - Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers - Google Patents
Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancersInfo
- Publication number
- SG10202111399YA SG10202111399YA SG10202111399YA SG10202111399YA SG10202111399YA SG 10202111399Y A SG10202111399Y A SG 10202111399YA SG 10202111399Y A SG10202111399Y A SG 10202111399YA SG 10202111399Y A SG10202111399Y A SG 10202111399YA SG 10202111399Y A SG10202111399Y A SG 10202111399YA
- Authority
- SG
- Singapore
- Prior art keywords
- peptides
- cancers
- combination
- breast cancer
- against breast
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562270968P | 2015-12-22 | 2015-12-22 | |
GBGB1522667.3A GB201522667D0 (en) | 2015-12-22 | 2015-12-22 | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10202111399YA true SG10202111399YA (en) | 2021-11-29 |
Family
ID=63849964
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202111399YA SG10202111399YA (en) | 2015-12-22 | 2016-11-29 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
Country Status (9)
Country | Link |
---|---|
US (11) | US10166278B2 (en) |
CL (6) | CL2018001531A1 (en) |
CY (1) | CY1124224T1 (en) |
HR (1) | HRP20210698T1 (en) |
IL (1) | IL258599A (en) |
PH (1) | PH12018500864A1 (en) |
SG (1) | SG10202111399YA (en) |
TW (3) | TWI720424B (en) |
ZA (1) | ZA201801036B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS62602B1 (en) | 2013-08-05 | 2021-12-31 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors, such as lung cancer including nsclc |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP4141002A1 (en) | 2015-11-19 | 2023-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
PL3394033T3 (en) | 2015-12-22 | 2021-05-31 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
TW201808950A (en) | 2016-05-06 | 2018-03-16 | 英塞特公司 | Heterocyclic compounds as immunomodulators |
MA45116A (en) | 2016-05-26 | 2021-06-02 | Incyte Corp | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS |
MX2018016273A (en) | 2016-06-20 | 2019-07-04 | Incyte Corp | Heterocyclic compounds as immunomodulators. |
EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
MA46045A (en) | 2016-08-29 | 2021-04-28 | Incyte Corp | HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS |
CN110582493B (en) | 2016-12-22 | 2024-03-08 | 因赛特公司 | Benzoxazole derivatives as immunomodulators |
MD3558990T2 (en) | 2016-12-22 | 2023-02-28 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as PD-L1 internalization inducers |
ES2899402T3 (en) | 2016-12-22 | 2022-03-11 | Incyte Corp | Pyridine derivatives as immunomodulators |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
SG11202009440WA (en) | 2018-03-30 | 2020-10-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
DK3790877T3 (en) | 2018-05-11 | 2023-04-24 | Incyte Corp | TETRAHYDRO-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 IMMUNE MODULATORS |
WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
US11401279B2 (en) | 2019-09-30 | 2022-08-02 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
TW202120504A (en) | 2019-11-11 | 2021-06-01 | 美商英塞特公司 | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
TW202233615A (en) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Crystalline form of a pd-1/pd-l1 inhibitor |
AU2021373044A1 (en) | 2020-11-06 | 2023-06-08 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
WO2024006821A2 (en) * | 2022-06-30 | 2024-01-04 | Lonza Sales Ag | Methods of treating a tumor |
CN116042823B (en) * | 2022-09-19 | 2024-03-29 | 广东省人民医院 | Molecular marker for esophageal squamous carcinoma prognosis and therapy efficacy evaluation and application thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9805877D0 (en) * | 1998-03-20 | 1998-05-13 | Imp Cancer Res Tech | Cancer |
US7211649B1 (en) * | 1999-07-02 | 2007-05-01 | Ana Mar Medical Ab | Cartilage intermediate layer protein |
EP2228446A1 (en) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Secreted and transmembrane polypeptieds and nucleic acids encoding the same |
EP1242049A4 (en) | 1999-12-13 | 2005-01-05 | Epimmune Inc | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
EP1306431B1 (en) | 2000-07-31 | 2008-03-19 | Green Peptide Co., Ltd. | Tumor antigen |
AU2001283463A1 (en) | 2000-08-18 | 2002-03-04 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer and screening for cancer modulators |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US6535424B2 (en) * | 2001-07-25 | 2003-03-18 | Advanced Micro Devices, Inc. | Voltage boost circuit using supply voltage detection to compensate for supply voltage variations in read mode voltage |
DE10225144A1 (en) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding to MHC molecules |
WO2005007090A2 (en) * | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
JP2008505648A (en) | 2004-07-07 | 2008-02-28 | メタボレックス インコーポレーティッド | Methods for diagnosis and treatment of diabetes and insulin resistance |
FR2894985B1 (en) | 2005-12-20 | 2008-01-18 | Alcan Rhenalu Sa | HIGH-TENACITY ALUMINUM-COPPER-LITHIUM PLASTER FOR AIRCRAFT FUSELAGE |
WO2008016356A2 (en) | 2006-08-02 | 2008-02-07 | Genizon Biosciences | Genemap of the human genes associated with psoriasis |
JP2011502964A (en) | 2007-10-23 | 2011-01-27 | ザ レジェンツ オブ ザ ユニバーシティ オブ コロラド | Competitive inhibitors of invariant chain expression and / or ectopic CLIP binding |
EP2119726B2 (en) | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
US10706955B2 (en) | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
EP2771349B1 (en) | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
EP2872530A4 (en) | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | Kif20a epitope peptides for th1 cells and vaccines containing the same |
GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
TWI776192B (en) * | 2013-08-05 | 2022-09-01 | 德商伊瑪提克斯生物科技有限公司 | Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same |
GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
-
2016
- 2016-11-29 SG SG10202111399YA patent/SG10202111399YA/en unknown
- 2016-12-22 TW TW108105097A patent/TWI720424B/en active
- 2016-12-22 TW TW111119458A patent/TW202241939A/en unknown
- 2016-12-22 TW TW109134386A patent/TWI768491B/en active
-
2018
- 2018-02-15 ZA ZA2018/01036A patent/ZA201801036B/en unknown
- 2018-04-10 IL IL258599A patent/IL258599A/en unknown
- 2018-04-23 PH PH12018500864A patent/PH12018500864A1/en unknown
- 2018-06-08 CL CL2018001531A patent/CL2018001531A1/en unknown
- 2018-06-29 US US16/024,164 patent/US10166278B2/en active Active
- 2018-06-29 US US16/024,142 patent/US10143733B2/en active Active
- 2018-06-29 US US16/024,133 patent/US10143732B2/en active Active
- 2018-11-01 US US16/177,919 patent/US10238728B2/en active Active
- 2018-12-05 US US16/210,357 patent/US10376569B2/en active Active
-
2019
- 2019-06-28 US US16/456,815 patent/US10485859B2/en active Active
- 2019-09-25 US US16/582,096 patent/US10596243B2/en active Active
- 2019-10-16 CL CL2019002941A patent/CL2019002941A1/en unknown
- 2019-10-16 CL CL2019002939A patent/CL2019002939A1/en unknown
- 2019-10-16 CL CL2019002940A patent/CL2019002940A1/en unknown
-
2020
- 2020-01-24 US US16/752,156 patent/US10675338B1/en active Active
- 2020-05-01 US US16/864,558 patent/US11065314B2/en active Active
-
2021
- 2021-05-05 HR HRP20210698TT patent/HRP20210698T1/en unknown
- 2021-05-28 US US17/333,902 patent/US20210290743A1/en active Pending
- 2021-06-10 CY CY20211100515T patent/CY1124224T1/en unknown
- 2021-09-29 CL CL2021002525A patent/CL2021002525A1/en unknown
- 2021-09-29 CL CL2021002524A patent/CL2021002524A1/en unknown
-
2022
- 2022-09-16 US US17/932,836 patent/US20230101093A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210709T8 (en) | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | |
ZA201801036B (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
SG10202005950XA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
HK1252868A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG10202001665QA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
SG11201706155XA (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
HK1255542A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | |
IL280879A (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |